To Get Full Access :

Zevtera

Zevtera is an advanced-generation cephalosporin antibiotic for treating Staphylococcus aureus bacteremia, including right-sided endocarditis, skin infections, and pneumonia in both adults and children. It works by blocking bacterial cell wall synthesis and remains active against MRSA and resistant strains.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Ceftobiprole Medocaril Sodium
  • Innovator :

    BASILEA PHARMACEUTICA INTERNATIONAL LTD ALLSCHWIL
  • Approval Date :

    03-Apr-24
  • NCE-1 Date :

    03-Apr-28
  • NCE Date :

    03-Apr-29
  • Dosage Form :

    Intravenous Powder Injection
  • Strength :

    667MG/VIAL
  • Therapeutic Category :

    Antibiotic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?